TB vaccine

TB vaccine in your own words

• 

  TB - my experiences

  This might sound odd, but I was really shocked when I became seriously ill because of HIV. I was even more shocked when it turned...

  From:In your own words

TB vaccine news from aidsmap

• Results of TB vaccine trial give cause for optimism, say researchers

  Results of a trial have been praised for “providing hard evidence about protection against tuberculosis in human beings”. The MVA85A vaccine did not confer any additional protection against tuberculosis (TB) or infection with Mycobacterium tuberculosis to infants who had ...

  04 February 2013 | Michael Carter

• BCG vaccination causes immune activation of CD4 T-cells in infants

  BCG vaccination, routinely given at birth to protect from tuberculosis (TB), causes an immune-activation of CD4 T cells, the HIV target cells, according to a South African study presented at the Nineteenth International AIDS Conference in Washington DC. This immune ...

  31 July 2012 | Lesley Odendal

• Therapeutic TB vaccine could reduce latent TB treatment to one month

  A vaccine, designed to be used alongside isoniazid preventive therapy to shorten the course of drug treatment in people with latent TB, will shortly undergo trials in South Africa, manufacturer Archivel Farma announced this week. Latent infection ...

  06 May 2010 | Keith Alcorn

• Trial of TB vaccine candidate begins in people with HIV

  Crucell and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial of the jointly developed tuberculosis (TB) vaccine candidate AERAS-402/Crucell Ad35 in HIV infected adults. The Phase II study is ...

  14 April 2010 | Press Release

More news

TB vaccine news selected from other sources

• Injection-free vaccination technique could address global vaccine challenge for diseases such as HIV and malaria

  Scientists at King’s College London have demonstrated the ability to deliver a dried live vaccine to the skin without a traditional needle, and shown for the first time that this technique is powerful enough to enable specialised immune cells in the skin to kick-start the immunising properties of the vaccine.

  11 February 2013 | Kings College London press release

• Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet

  Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with BCG.

  04 February 2013 | Aeras

• TB Vaccine Safe but Does Not Confer Protection, Calls for Redoubling Efforts on Global TB Vaccine Portfolio

  The clinical trial of the TB vaccine candidate MVA85A was a Phase IIb safety and efficacy trial in 2,797 infants living in the Western Cape province of South Africa. The candidate was safe and well tolerated in the population tested.

  04 February 2013 | Aeras

• Revived search for a TB vaccine may be about to pay off

  After nearly 100 years, researchers could be on the verge of finding a vaccine that would eradicate tuberculosis infections, a scourge that kills 1.4 million people a year.

  04 February 2013 | Reuters

• HEALTH: New TB vaccine on the horizon

  A research team at Oxford University in the UK is very close to determining the efficacy of their new tuberculosis (TB) vaccine. If current clinical trials are successful, it will be the first new TB vaccine in almost a century.

  17 October 2012 | IRIN Plus News

• Green light for start clinical trials of innovative and promising tuberculosis vaccine

  European scientists are one step closer to delivering a new, safe and more effective vaccine against tuberculosis. Swiss-medic, the Swiss regulatory authority for medicine has given permission to start assessing the new TB vaccine in healthy adult volunteers. The vaccine, called MTBVAC, is the first vaccine of its kind to start clinical evaluation.

  17 October 2012 | TB vaccine Initiative

• Aeras signs agreement with GSK to jointly advance TB vaccine

  Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01E* adjuvant.

  10 October 2012 | Eurekalert Medicine & Health

• Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains

  The National Institutes of Health has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis, including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant.

  31 May 2012 | Eurekalert Inf Dis

• Experts, Advocates Urge Continued Funding For Research Into HIV, TB Vaccines

  "[P]articipants at a symposium held last week by the U.K. Consortium on AIDS and International Development warned that [progress on HIV and tuberculosis (TB) vaccines] could be jeopardized by the recent downturn in global health funding," BMJ reports.

  23 May 2012 | Kaiser Daily Global Health Policy Report

• PDPs agree to jointly develop new TB vaccine candidate

  Aeras and the Infectious Disease Research Institute (IDRI) – two non-profit product development partnerships (PDPs) – announced Wednesday they will be joining together to develop IDRI’s novel tuberculosis (TB) vaccine candidate ID93/GLA-SE.

  10 May 2012 | Science Speaks

More news